US FDA's Biosimilar User Fees Could Be Raised Significantly In Renewal Talks
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration may be looking for more money from biosimilar sponsors as part of the reauthorization for the user fee program, BsUFA.